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One Size Does Not 
Fit All Lung Cancer 
Patients
In Response:
We thank Drs. Jeremic and Videtic 
for highlighting points related to our arti-
cle.1 We concur that the standard of care 
for eligible patients with unresectable 
stage III non–small-cell lung cancer is 
concurrent chemoradiation, as proven in 
phase III randomized trials. In our intro-
duction, we described our study rationale. 
For patients who have poor performance 
status, unduly large radiotherapy fields, 
or medical comorbidities that make 
upfront chemoradiation unrealistic or 
even risky, sequential chemoradiother-
apy is an alternative that is preferable to 
radiotherapy alone.2 It is understood that 
these patients represent a different popu-
lation than that represented in concurrent 
chemoradiation trials.
There is a request for justification 
for future clinical research. However, 
we are not proposing more prospective 
studies of induction-chemotherapy strat-
egies. This was neither the goal nor the 
main point of our study. Nonetheless, 
as the issue has now been raised, it is 
worth mentioning that the question 
of induction chemotherapy has not 
been entirely settled for poor-prognosis 
patients. A randomized phase II study, 
Locally Advanced Multi-Modality 
Protocol, included an arm of induc-
tion carboplatin/paclitaxel followed by 
concurrent chemoradiation. The induc-
tion arm produced lower median survival, 
but more patients with low Karnofsky 
performance status, male sex, and weight 
loss received induction; in addition, the 
trial accrued slowly and closed early.3 
The cancer and leukemia group B 39801 
phase III study randomized patients to 
either two cycles of carboplatin/pacli-
taxel followed by concurrent chemoradi-
ation versus concurrent chemoradiation 
alone. The median overall survival was 
longer in the induction arm (14 months 
versus 12 months), but this difference 
was not statistically significant, and both 
arms underperformed relative to histori-
cal controls. With more than 5% weight 
loss, survival was longer with induc-
tion, a finding that was not significant 
on detailed reanalysis. However, it was 
noted that prognostic factors were highly 
determinant of outcome, raising ques-
tions about the benefit of chemoradiation 
in these patients.4 None of these studies 
addressed the issue of which approach 
was to be adopted for patients unable 
to have upfront concurrent chemoradia-
tion or whose overall prognosis was so 
poor as to put the benefit of concurrent 
chemoradiation in doubt.
Regardless of what we all may 
consider optimal, many patients have 
received induction chemotherapy before 
subsequent definitive or palliative treat-
ment. We intended to present our expe-
riences with these patients who were 
treated off clinical trials. We included 
available prognostic factors and other 
variables in our study, such as patient 
demographics, performance status, and 
type of induction chemotherapy used. 
Nonetheless, we acknowledge that this 
retrospectively selected population 
sample is small and heterogeneous.
It has been estimated that as 
many as 59% of patients with locally 
advanced lung cancer are ineligible for 
concurrent chemoradiation at presenta-
tion.5 We believe there will be continued 
use of induction regimens off protocol 
for certain classes of high-risk or poor-
prognosis patients. Information from 
studies such as ours can help manage 
expectations and optimize outcomes in 
these difficult situations. We thank our 
colleagues for their interest in our work.
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